Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.73 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.73 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.73 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | EFNA1 | P20827 | 1/20 | 0.73 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.73 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.73 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.73 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.73 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.73 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | VDR | P11473 | 6/20 | 0.72 |
| ▸ | CASP7 | P55210 | 3/20 | 0.72 |
| ▸ | TP53 | P04637 | 2/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4624060 | 1.00 | GPBAR1 (0.73) | GPBAR1HSD17B10TDP1AKR1B10AKR1B1 | |
| SCHEMBL10385209 | 0.91 | GPBAR1 (0.73) | GPBAR1HSD17B10TDP1AKR1B10AKR1B1 | |
| SCHEMBL26670107 | 0.91 | GPBAR1 (0.73) | GPBAR1HSD17B10TDP1AKR1B10AKR1B1 | |
| SCHEMBL11573740 | 0.90 | GPBAR1 (0.60) | GPBAR1HSD17B10TDP1AKR1B10AKR1B1 | |
| SCHEMBL23937024 | 0.89 | GPBAR1 (0.70) | GPBAR1HSD17B10TDP1AKR1B10AKR1B1 | |
| SCHEMBL19864272 | 0.89 | GPBAR1 (0.70) | GPBAR1HSD17B10TDP1AKR1B10AKR1B1 | |
| SCHEMBL19864253 | 0.89 | GPBAR1 (0.73) | GPBAR1HSD17B10TDP1AKR1B10AKR1B1 | |
| SCHEMBL18575773 | 0.89 | GPBAR1 (0.73) | GPBAR1HSD17B10TDP1AKR1B10AKR1B1 | |
| SCHEMBL29120311 | 0.89 | GPBAR1 (0.73) | GPBAR1HSD17B10TDP1AKR1B10AKR1B1 | |
| SCHEMBL30620024 | 0.89 | GPBAR1 (0.73) | GPBAR1HSD17B10TDP1AKR1B10AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3538159-A1 | INHIBITION OF FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE PATIENTS | Galmed Research and Development Ltd. (IL) | 2019-09-18 | — | — | EP | claimed |
| WO-2018087600-A1 | INHIBITION OF FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE PATIENTS | GALMED RESEARCH AND DEVELOPMENT LTD. (IL) | 2018-05-17 | — | — | WO | claimed |
| EP-3030221-A1 | ANTI-AGING COMPOSITIONS COMPRISING BILE ACID-FATTY ACID CONJUGATES | Galderm Therapeutics Ltd. (IL) | 2016-06-15 | — | — | EP | claimed |
| WO-2015019358-A1 | ANTI-AGING COMPOSITIONS COMPRISING BILE ACID-FATTY ACID CONJUGATES | GALDERM THERAPEUTICS LTD. (IL) | 2015-02-12 | — | — | WO | claimed |
| US-20140377798-A1 | PROCESS FOR THE ENZYMATIC REGENERATION OF REDOX COFACTORS | ANNIKKI GMBH (AT) | 2014-12-25 | — | — | US | claimed |
| JP-7017867-A | — | — | None | — | — | JP | disclosed |
| JP-62061920-A | — | — | None | — | — | JP | disclosed |
| WO-2023081657-A2 | HIGH PURITY NON-ANIMAL DERIVED UDCA | SANDHILL ONE, LLC (US) | 2023-05-11 | — | — | WO | disclosed |
| US-11166964-B2 | Treatment for modulating gut microbiota | GALMED RESEARCH AND DEVELOPMENT LTD (IL) | 2021-11-09 | — | — | US | disclosed |
| US-20210169901-A1 | TREATMENT FOR MODULATING GUT MICROBIOTA | GALMED RESEARCH AND DEVELOPMENT LTD. (IL) | 2021-06-10 | — | — | US | disclosed |
| EP-3538159-A1 | INHIBITION OF FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE PATIENTS | Galmed Research and Development Ltd. (IL) | 2019-09-18 | — | — | EP | disclosed |
| EP-3464315-A1 | METHODS FOR THE PREPARATION OF DEOXYCHOLIC ACID, AND INTERMEDIATES USEFUL IN THE PREPARATION OF DEOXYCHOLIC ACID | Bionice, S.L.U. (ES) | 2019-04-10 | — | — | EP | disclosed |
| WO-1999001579-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF OLIGONUCLEOTIDES VIA THE ALIMENTARY CANAL | ISIS PHARMACEUTICALS, INC. (US) | 1999-01-14 | — | — | WO | disclosed |
| JP-H0717867-A | MEDICINE FOR TREATING ILLNESSES OF RESPIRATORY ORGAN | MEDICHEMIE AG | 1995-01-20 | — | — | JP | disclosed |
| US-5260074-A | Compositions of digestive enzymes and salts of bile acids and process for preparation thereof | DIGESTIVE CARE INC. (US) | 1993-11-09 | — | — | US | disclosed |
| JP-S6261920-A | AGENT FOR IMPROVING HEPATIC FUNCTION | TOKYO TANABE CO LTD | 1987-03-18 | — | — | JP | disclosed |
| US-4263272-A | FOR LYSIS OF CHOLESTEROL CALCULI | LEHNER AG (CH) | 1981-04-21 | — | — | US | disclosed |
| US-4079133-A | Safer method for dissolving gallstones combining hyodeoxycholic acid with chenodeoxycholic acids | WARREN-TEED LABORATORIES, INC. (US) | 1978-03-14 | — | — | US | disclosed |
| US-3957983-A | ANTIBIOTICS | INTELLECTUAL PROPERTY DEVELOPMENT CORPORATION (US) | 1976-05-18 | — | — | US | disclosed |
| US-3931256-A | Chemical process for production of bile acids | INTELLECTUAL PROPERTY DEVELOPMENT CORPORATION (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210169901-A1 | TREATMENT FOR MODULATING GUT MICROBIOTA | NR1H4, SLC10A2, FABP2 | GPBAR1 4/4885HSD17B10 196/4885TDP1 4510/4885 |
| US-11166964-B2 | Treatment for modulating gut microbiota | NR1H4, SLC10A2, FABP2 | GPBAR1 4/4885HSD17B10 196/4885TDP1 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.